SCHEMBL5365029

SCHEMBL5365029

O=C(O)c1ccc(NC(=S)NN=Cc2cccc(-c3cccc(Cl)c3)c2O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
GAA P10253 7/20 0.52
KDM4E B2RXH2 7/20 0.52
SMN1; SMN2 Q16637 7/20 0.52
RAB9A P51151 8/20 0.47
NPC1 O15118 7/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RRM1 P23921 1/20 0.46
RRM2 P31350 1/20 0.46
RRM2B Q7LG56 1/20 0.46
HSP90AA1 P07900 1/20 0.46
ALDH1A1 P00352 5/20 0.43
HDAC8 Q9BY41 1/20 0.43
PKM P14618 3/20 0.42
MITF O75030 2/20 0.42
PAX8 Q06710 1/20 0.42
KLF5 Q13887 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365026 1.00 MAPT (0.52) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5364925 0.91 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5364928 0.91 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5365939 0.86 SMN1; SMN2 (0.50) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5365944 0.86 SMN1; SMN2 (0.50) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5365385 0.85 GAA (0.54) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5365381 0.85 GAA (0.54) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5365623 0.85 MAPT (0.54) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5365615 0.85 MAPT (0.54) MAPTGAAKDM4ESMN1; SMN2RAB9A
SCHEMBL5372825 0.84 MAPT (0.54) MAPTGAAKDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885GAA 3120/4885KDM4E 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.